We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

WelChol® With Metformin in Treating Patients With Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00147719
Recruitment Status : Completed
First Posted : September 7, 2005
Last Update Posted : January 18, 2012
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to metformin alone or in combination with other anti-diabetic drugs.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Drug: Colesevelam hydrochloride Phase 3

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Monotherapy or Metformin Therapy in Combination With Other Oral Anti-Diabetic Agents
Study Start Date : June 2004
Primary Completion Date : July 2006
Study Completion Date : July 2006

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. To assess the additional lowering of HbA1C achieved by addition of colesevelam hydrochloride to current antidiabetic therapy

Secondary Outcome Measures :
  1. To assess the fasting plasma glucose and fructosamine lowering effect;
  2. To assess the glycemic control response rate;
  3. To assess the improvement in insulin sensitivity;
  4. To assess the effect on high sensitivity C-reactive protein;
  5. To assess the improvement in lipids, and lipoproteins;
  6. To assess the safety and tolerability of colesevelam hydrochloride when added on to current therapy

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18-75 years, inclusive
  • Diagnosed with type 2 diabetes
  • Hemoglobin (HbA1c) between 7.5% to 9.5%
  • Prescribed an ADA accepted diet
  • Receiving stable dose of metformin alone or in combination with other oral anti-diabetic medications for 90 days before Visit 1

Exclusion Criteria:

  • History of type 1 diabetes or ketoacidosis
  • History of chronic (more than 2 months) insulin therapy or the initiation of insulin for chronic treatment
  • History of pancreatitis
  • Uncontrolled hypertension
  • Recent severe cardiovascular disease
  • Allergy or toxic response to colesevelam or any of its components
  • Body mass index (BMI) >45 kg/m2
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00147719

  Hide Study Locations
United States, Arkansas
Jonesboro, Arkansas, United States
United States, California
Beverly Hills, California, United States
Carmichael, California, United States
Fresno, California, United States
Irvine, California, United States
La Jolla, California, United States
Los Gatos, California, United States
San Diego, California, United States
Spring Valley, California, United States
West Hills, California, United States
United States, District of Columbia
Washington, District of Columbia, United States
United States, Florida
Coco Beach, Florida, United States
Largo, Florida, United States
Miami, Florida, United States
Pembroke Pines, Florida, United States
West Palm Beach, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
United States, Indiana
Evansville, Indiana, United States
United States, Kentucky
Louisville, Kentucky, United States
United States, Michigan
Detroit, Michigan, United States
Troy, Michigan, United States
United States, Minnesota
Edina, Minnesota, United States
United States, Missouri
Chesterfield, Missouri, United States
United States, Montana
Bozeman, Montana, United States
Butte, Montana, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, New York
Rochester, New York, United States
United States, North Carolina
Charlotte, North Carolina, United States
Winston-Salem, North Carolina, United States
United States, Ohio
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Lyndhurst, Ohio, United States
Marion, Ohio, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
Tulsa, Oklahoma, United States
United States, Oregon
Portland, Oregon, United States
United States, Pennsylvania
Beaver, Pennsylvania, United States
United States, South Carolina
Charleston, South Carolina, United States
Columbia, South Carolina, United States
United States, Tennessee
Morristown, Tennessee, United States
United States, Texas
Corpus Christi, Texas, United States
Dallas, Texas, United States
Pharr, Texas, United States
San Antonio, Texas, United States
United States, Virginia
Arlington, Virginia, United States
Richmond, Virginia, United States
Mexico DF, Mexico
Lima, Peru
Sponsors and Collaborators
Daiichi Sankyo, Inc.
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Daiichi Sankyo, Inc.
ClinicalTrials.gov Identifier: NCT00147719     History of Changes
Other Study ID Numbers: WEL-301
First Posted: September 7, 2005    Key Record Dates
Last Update Posted: January 18, 2012
Last Verified: January 2012

Keywords provided by Daiichi Sankyo, Inc.:
Diabetes Mellitus

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Colesevelam Hydrochloride
Hypoglycemic Agents
Physiological Effects of Drugs
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents